xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

287

Orlandi et al.

Chen 362 2001 3* Questionnaire (n = 8723) Children in Taiwan RS Children reporting allergy more likely to have RS Sinus CT abnormality 60% had CT abnormalities

common during high pollen season

TABLE VII-6 Evidence for allergy as a contributing factor for ARS Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Lin 351 2019 2 Cross sectional cohort (n = 43,588) Taiwanese children with- and withoutAR Incidence of ARS Risk of ARS higher in allergic patients than non-allergic patients (adjusted hazard ratio 3.03) Frerichs 355 2014 2 Systematic review Allergic and nonallergic patients Prolonged course ( > 4weeks) ofRS No significant increase in prolonged RS

causes increased eosinophils in the maxillary sinus

Risk of ARS was significantly higher with a physician diagnosis of AR (OR 1.70)

No significant difference in incidence of ARS among children with AR and non-allergic controls

Individuals with atopic disease had higher risk of developing URIs including RS

Adjunctive loratadine improved sneezing at 14 days, and cough

and nasal congestion at 28 days

maxillary sinusitis and 16.5% in controls

Prevalence of AR Orbital complications more

ARS Prevalence of AR 25% in acute

representing 50% response rate) Dutch adults Risk factors for AR, ARS, and CRS

Eosinophils in maxillary sinus Nasal challenge with allergen Overall and individual symptom scores improvement at 28 days Incidence of ARS during allergen season

Upper and lower respiratory tract infections

Naclerio 359 1997 3 Observational (n = 10) Allergic subjects at peak allergy season complications of ARS

Allergic subjects who underwent nasal challenge; Controls

Children with AR vs non-allergic control group

Rantala 352 2013 2 Cross-sectional (n = 1008) Atopic and nonatopic adults age 21-63 Baroody 358 2008 2 DB randomized placebo controlled crossover (n = 20)

Comorbid AR and ARS; treated with amoxicillin-clavulanate plus steroid or

amoxicillin-clavulanate plus steroid plus loratadine

Savolainen 350 1989 4 Case control (n = 224) Acute maxillary sinusitis with and without allergy compared to controls without maxillary sinusitis

Holzmann 354 2001 4** Retrospective review (n = 102) Children with orbital

Hoffmans 353 2018 3* Questionnaire (n = 8347,

Leo 357 2018 3 Observational case-control study (n = 242; control n = 65)

Braun 356 1997 2 DBPC parallel group RCT (n = 139)

*LOE downgraded due to study design (self-reported ARS) **LOE downgraded due to sample size (n = 102)